EX-4.1



 Exhibit 4.1 

THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS, AND MAY
NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR PURSUANT TO RULE 144 OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND ANY APPLICABLE
STATE SECURITIES LAWS. 
 Warrant No. [    ] 

WARRANT AGREEMENT 
 To
Purchase Shares of the Common Stock of 
 Cleveland BioLabs, Inc. 

Dated as of [            ] (the “Effective Date”) 

WHEREAS, Cleveland BioLabs, Inc., a Delaware corporation (the “Company”), has entered into a Securities Purchase Agreement of
even date herewith (the “Securities Purchase Agreement”) with, among others, [            ] (the “Warrantholder”); 

WHEREAS, pursuant to the Securities Purchase Agreement and as additional consideration to the Warrantholder for, among other things, its
investment in the Company’s Common Stock, the Company has agreed to issue to the Warrantholder this Warrant Agreement, evidencing the right to purchase shares of the Company’s Common Stock (this “Warrant” or this
“Agreement”); 
 NOW, THEREFORE, in consideration of the Warrantholder having executed and delivered the Securities
Purchase Agreement, and in consideration of the mutual covenants and agreements contained herein, the Company and Warrantholder agree as follows: 

SECTION 1. GRANT OF THE RIGHT TO PURCHASE COMMON STOCK. 

(a) For value received, the Company hereby grants to the Warrantholder, and the Warrantholder is entitled, upon the terms and subject to
the conditions hereinafter set forth, to subscribe for and purchase, from the Company, up to such number of shares of Common Stock (as defined below) as determined in Section 1(b) below, at a purchase price per share equal to the Exercise Price
(as defined below). The number and Exercise Price of such shares are subject to adjustment as provided in Section 8. As used herein, the following terms shall have the following meanings: 

“Act” means the Securities Act of 1933, as amended. 

“Charter” means the Company’s Certificate of Incorporation or other constitutional document, as may be amended and in
effect from time to time. 

  
 1 








 “Common Stock” means the Company’s common stock, $0.005 par value per
share, as presently constituted under the Charter, and any class and/or series of Company capital stock for or into which such common stock may be converted or exchanged in a reorganization, recapitalization or similar transaction. 

“Exercise Price” means $0.56, subject to adjustment from time to time in accordance with the provisions of this Warrant. 

“Exercise Shares” shall mean the shares of the Company’s Common Stock issued or issuable upon exercise of this Warrant,
subject to adjustment pursuant to the terms herein, including, but not limited to, adjustment pursuant to Section 8 below. 

“Liquid Sale” means the closing of a Merger Event in which the consideration received by the Company and/or its stockholders,
as applicable, consists solely of cash and/or Marketable Securities. 
 “Marketable Securities” in connection with a Merger
Event means securities meeting all of the following requirements: (i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), and is then current in its filing of all required reports and other information under the Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that would be received by
the Warrantholder in connection with the Merger Event were the Warrantholder to exercise this Warrant on or prior to the closing thereof is then traded on a national securities exchange or over-the-counter market, and (iii) the Warrantholder
would not be restricted by contract or by applicable federal and state securities laws from publicly re-selling, within six (6) months and one day following the closing of such Merger Event, all of the issuer’s shares and/or other
securities that would be received by the Warrantholder in such Merger Event were the Warrantholder to exercise this Warrant in full on or prior to the closing of such Merger Event. 

“Merger Event” means any of the following: (i) a sale, lease or other transfer of all or substantially all assets of the
Company, (ii) any merger or consolidation involving the Company in which the Company is not the surviving entity or in which the outstanding shares of the Company’s capital stock are otherwise converted into or exchanged for shares of
capital stock or other securities or property of another entity, or (iii) any sale by holders of the outstanding voting equity securities of the Company in a single transaction or series of related transactions of shares constituting a majority
of the outstanding combined voting power of the Company. 
 “Purchase Price” means, with respect to any exercise of this
Warrant, an amount equal to the then-effective Exercise Price multiplied by the number of shares of Common Stock as to which this Warrant is then exercised. 

(b) Number of Shares. This Warrant shall be exercisable for
[            ] shares of Common Stock, subject to adjustment from time to time in accordance with the provisions of this Warrant. 

  
 2 








 SECTION 2. TERM OF THE AGREEMENT. 

The term of this Agreement and the right to purchase Common Stock as granted herein shall commence on the Effective Date and shall be
exercisable for a period ending on the fifth (5th) anniversary of the Effective Date. 

SECTION 3. EXERCISE OF THE PURCHASE RIGHTS. 

(a) Exercise. The purchase rights set forth in this Agreement are exercisable by the Warrantholder, in whole or in part, at any
time, or from time to time, prior to the expiration of the term set forth in Section 2 and in accordance with Section 3(b), by tendering to the Company at its principal office a notice of exercise in the form attached hereto as Exhibit I
(the “Notice of Exercise”), duly completed and executed. No ink-original Notice of Exercise shall be required, and provided that the shares of Common Stock are being issued in the name of the Warrantholder as written above, a
medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise Form shall not be required. Notwithstanding anything herein to the contrary, the Warrantholder shall not be required to physically surrender this Warrant to
the Company. Promptly upon receipt of the Notice of Exercise and the payment of the Purchase Price in accordance with the terms set forth below (the “Exercise Shares Delivery Date”), the Company shall, as specified in the Notice of
Exercise, (i) no later than three (3) business days thereafter, issue to the Warrantholder a certificate for the number of shares of Common Stock purchased and deliver the certificate to an address in the United States as instructed by the
Warrantholder or (ii) no later than three (3) business days thereafter, cause the shares of Common Stock purchased to be made available to the Warrantholder via the Depository Trust Company’s Deposit or Withdrawal at Custodian
(“DWAC”) system if the shares are eligible for such transfer, or (iii) no later than seven (7) Trading Days thereafter, issue to the Warrantholder a certificate for the number of shares of Common Stock purchased and
deliver the certificate to an address in Russia as instructed by the Warrantholder. The Company shall also execute and deliver to the Warrantholder the acknowledgment of exercise in the form attached hereto as Exhibit II (the “Acknowledgment
of Exercise”) indicating the number of shares which remain subject to future purchases under this Warrant, if any. 
 (b) The
Purchase Price may be paid at the Warrantholder’s election either (i) by cash or check, or (ii) by surrender of all or a portion of the Warrant for shares of Common Stock to be exercised under this Agreement and, if applicable, an
amended Agreement setting forth the remaining number of shares purchasable hereunder, in accordance with the formula set forth below (“Net Issuance”). If the Warrantholder exercises the Warrant by utilizing the Net Issuance method,
the Company will issue shares of Common Stock in accordance with the following formula: 
  

					
	         X = Y(A-B)

A     
	  	
			
	Where:	  	X =	  	the number of shares of Common Stock to be issued to the Warrantholder.
			
		  	Y =	  	the number of shares of Common Stock requested to be exercised under this Agreement.


  
 3 









					
			
	    	  	A =	  	the then-current fair market value of one (1) share of Common Stock at the time of exercise.
			
		  	B =	  	the then-effective Exercise Price.

 For purposes of the above calculation, the current fair market value of shares of Common Stock shall mean with
respect to each share of Common Stock: 
 (i) at all times when the Common Stock shall be traded on a national securities exchange,
inter-dealer quotation system or over-the-counter bulletin board service, the daily volume weighted average price of the Common Stock on the Trading Day immediately preceding the date on which the Warrantholder elects to exercise the Warrant;

 (ii) if the exercise is in connection with a Merger Event pursuant to Section 3(c) below, the per share value received by
the holders of the outstanding shares of Common Stock pursuant to the Merger Event as determined in accordance with the definitive transaction documents executed among the parties in connection with such Merger Event; or 

(iii) in cases other than as described in the foregoing clauses (i) and (ii), the current fair market value of a share of Common
Stock shall be determined in good faith by the Company’s Board of Directors. 
 Notwithstanding anything herein to the contrary,
on the Termination Date or if the exercise is in connection with a Merger Event, this Warrant shall be automatically exercised via cashless exercise pursuant to Section 3(b) or Section 3(c), as applicable. 

(c) Merger Event. In addition to any notice required pursuant to Section 8(d) below, the Company shall give Warrantholder at
least ten (10) business days’ written notice prior to consummating a Merger Event (the “Merger Event Notice”). To the extent this Warrant is not previously exercised as to all shares subject hereto, this Warrant shall be
deemed automatically exercised on a net exercise basis (even if not surrendered) as of immediately prior to the Merger Event pursuant to Section 3(b). The consideration per Warrant share distributable to the Warrantholder in connection such
Merger Event will consist of (a) if such Merger Event is a Liquid Sale, cash, cash equivalents or Marketable Securities (or any combination thereof) in an amount equal to the fair-market value of one share of Common Stock (determined in
accordance with Section 3(b)(ii)) minus the Exercise Price or (b) if the Merger Event is not a Liquid Sale, cash, cash equivalents, Marketable Securities, securities or other property (or any combination thereof) equal to the fair-market
value of one share of Common Stock (determined in accordance with Section 3(b)(ii)) minus the Exercise Price or (ii) if the then-current fair market value of one share of Common Stock (determined in accordance with Section 3(b)(ii))
is equal to or less than the Exercise Price then in effect, this Warrant shall be deemed to automatically expire (even if not surrendered) as of immediately prior to the Merger Event. 

(d) [Exercise Limitation. The Company shall not effect any exercise of this Warrant, and a Warrantholder shall not have the right
to exercise any portion of this Warrant, pursuant to Section 3 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Warrantholder (together with the
Warrantholder’s 

  
 4 








 
affiliates, and any other persons acting as a group together with the Warrantholder or any of the Warrantholder’s affiliates), would beneficially own in excess of the Beneficial Ownership
Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Warrantholder and its affiliates shall include the number of shares of Common Stock issuable upon exercise of
this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by
the Warrantholder or any of its affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock equivalents) subject to a
limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Warrantholder or any of its affiliates. Except as set forth in the preceding sentence, for purposes of this Section 3(d),
beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Warrantholder that the Company is not representing to the
Warrantholder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Warrantholder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained
in this Section 3(d) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Warrantholder together with any affiliates) and of which portion of this Warrant is exercisable shall be in the
sole discretion of the Warrantholder and the submission of a Notice of Exercise shall be deemed to be the Warrantholder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the Warrantholder together
with any affiliates) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no
liability for exercise of the Warrant that are not in compliance with the Beneficial Ownership Limitation. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the
Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 3(d), in determining the number of outstanding shares of Common Stock, a Warrantholder may rely on the number of outstanding shares of Common Stock
as reflected in (A) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the
transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Warrantholder, the Company shall within two (2) business days confirm orally and in writing to the Warrantholder the
number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the
Warrantholder or its affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 9.99% of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of
this Section 3(d) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly
give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.] 

  
 5 








 (e) Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon
Exercise. In addition to any other rights available to the Warrantholder, if the Company fails to cause its transfer agent to transmit to the Warrantholder the Exercise Shares on or before the Exercise Shares Delivery Date in accordance with the
Notice of Exercise pursuant to an exercise, and if after such date the Warrantholder is required by its broker to purchase (in an open market transaction or otherwise) or the Warrantholder’s brokerage firm otherwise purchases, shares of Common
Stock to deliver in satisfaction of a sale by the Warrantholder of the Warrant Shares which the Warrantholder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Warrantholder
the amount, if any, by which (x) the Warrantholder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of
Exercise Shares that the Company was required to deliver to the Warrantholder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option
of the Warrantholder, either reinstate the portion of the Warrant and equivalent number of Exercise Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Warrantholder the number of
shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. The Warrantholder shall provide the Company written notice indicating the amounts payable to the Warrantholder
in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Warrantholder’s right to any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. 

SECTION 4. RESERVATION OF SHARES. 

During the term of this Agreement, the Company will at all times have authorized and reserved a sufficient number of shares of its Common Stock
to provide for the exercise of the rights to purchase Common Stock as provided for herein. 
 SECTION 5. NO FRACTIONAL SHARES OR SCRIP.

 No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Agreement, but in lieu of such
fractional shares the Company shall make a cash payment therefor upon the basis of the Exercise Price then in effect. 
 SECTION 6. NO
RIGHTS AS STOCKHOLDER. 
 Without limitation of any provision hereof, Warrantholder agrees that this Agreement does not entitle the
Warrantholder to any voting rights or other rights as a stockholder of the Company prior to the exercise of any of the purchase rights set forth in this Agreement. 

  
 6 








 SECTION 7. WARRANTHOLDER REGISTRY. 

The Company shall maintain a registry showing the name and address of the registered holder of this Agreement. Warrantholder’s initial
address, for purposes of such registry, is set forth in Section 12(e) below. Warrantholder may change such address by giving written notice of such changed address to the Company. 

SECTION 8. ADJUSTMENT RIGHTS. 

The Exercise Price and the number of shares of Common Stock purchasable hereunder are subject to adjustment from time to time, as follows: 

(a) Reclassification of Shares. If the Company at any time shall, by combination, reclassification, exchange or subdivision of
securities or otherwise, change any of the securities as to which purchase rights under this Agreement exist into the same or a different number of securities of any other class or classes of securities, this Agreement shall thereafter represent the
right to acquire such number and kind of securities as would have been issuable as the result of such change with respect to the securities which were subject to the purchase rights under this Agreement immediately prior to such combination,
reclassification, exchange, subdivision or other change. The provisions of this Section 8(a) shall similarly apply to successive combination, reclassification, exchange, subdivision or other change. 

(b) Subdivision or Combination of Shares. If the Company at any time shall combine or subdivide its Common Stock, (i) in the
case of a subdivision, the Exercise Price shall be proportionately decreased and the number of shares for which this Warrant is exercisable shall be proportionately increased, or (ii) in the case of a combination, the Exercise Price shall be
proportionately increased and the number of shares for which this Warrant is exercisable shall be proportionately decreased. 
 (c)
Stock Dividends. If the Company at any time while this Agreement is outstanding and unexpired shall: 
 (i) pay a dividend
with respect to the outstanding shares of Common Stock payable in additional shares of Common Stock, then the Exercise Price shall be adjusted, to that price determined by multiplying the Exercise Price in effect immediately prior to such date of
determination by a fraction (A) the numerator of which shall be the total number of shares of Common Stock outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the total number of shares
of Common Stock outstanding immediately after such dividend or distribution, and the number of shares of Common Stock for which this Warrant is exercisable shall be proportionately increased; or 

(ii) make any other dividend or distribution on or with respect to Common Stock, except any dividend or distribution (A) in cash,
or (B) specifically provided for in any other clause of this Section 8, then, in each such case, provision shall be made by the Company such that the Warrantholder shall receive upon exercise or conversion of this Warrant a proportionate
share of any such distribution as though it were the holder of the Common Stock (or other stock for which the Common Stock is convertible) as of the record date fixed for the determination of the shareholders of the Company entitled to receive such
distribution. 

  
 7 








 (d) Notice of Certain Events. If: (i) the Company shall declare any dividend
or distribution upon its outstanding Common Stock, payable in stock, cash, property or other securities; (ii) the Company shall offer for subscription pro rata to the holders of its Common Stock any additional shares of stock of any class or
other rights; (iii) there shall be any Merger Event; or (iv) there shall be any voluntary dissolution, liquidation or winding up of the Company; then, in connection with each such event, the Company shall give the Warrantholder notice
thereof at the same time and in the same manner as it gives notice thereof to the holders of Common Stock. 
 SECTION 9. REPRESENTATIONS,
WARRANTIES AND COVENANTS OF THE COMPANY. 
 (a) Reservation of Common Stock. The Company covenants and agrees that all
shares of Common Stock, if any, that may be issued upon the exercise of the rights represented by this Warrant will, upon issuance, be validly issued and outstanding, fully paid and non-assessable. The Company further covenants and agrees that the
Company will, at all times during the term hereof, have authorized and reserved, free from preemptive rights, a sufficient number of shares of Common Stock to provide for the exercise of the rights represented by this Warrant. If at any time during
the term hereof the number of authorized but unissued shares of Common Stock shall not be sufficient to permit exercise of this Warrant in full, the Company will take such corporate action as may, in the opinion of its counsel, be necessary to
increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes. 
 (b)
Due Authority. The execution and delivery by the Company of this Agreement and the performance of all obligations of the Company hereunder, including the issuance to Warrantholder of the right to acquire the shares of Common Stock, have
been duly authorized by all necessary corporate action on the part of the Company. This Agreement: (1) does not violate the Company’s Charter or current bylaws; (2) does not contravene any law or governmental rule, regulation or order
applicable to it; and (3) except as could not reasonably be expected to have a Material Adverse Effect (as defined in the Securities Purchase Agreement), does not and will not contravene any provision of, or constitute a default under, any
indenture, mortgage, contract or other instrument to which it is a party or by which it is bound. This Agreement constitutes a legal, valid and binding agreement of the Company, enforceable in accordance with its terms, except as may be limited by
bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting creditors’ rights generally (including, without limitation, fraudulent conveyance laws) and by general principles of equity, regardless of whether
considered in a proceeding in equity or at law. 
 (c) Consents and Approvals. No consent or approval of, giving of notice to,
registration with, or taking of any other action in respect of any state, federal or other governmental authority or agency is required with respect to the execution, delivery and performance by the Company of its obligations under this Agreement,
except for the filing of notices pursuant to Regulation D under the Act and any filing required by applicable state securities law, which filings will be effective by the time required thereby. 

  
 8 








 (d) Exempt Transaction. Subject to the accuracy of the Warrantholder’s
representations in Section 10, the issuance of the Common Stock upon exercise of this Agreement will constitute a transaction exempt from (i) the registration requirements of Section 5 of the Act, in reliance upon Section 4(2)
thereof, and (ii) the qualification requirements of the applicable state securities laws. 
 (e) Rule 144 Compliance.
Subject to the provisions included in the Registration Rights Agreement dated June 17, 2014, the Company shall, at all times prior to the earlier to occur of (x) the date of sale or other disposition by Warrantholder of this Warrant or all
shares of Common Stock issued on exercise of this Warrant, (y) the registration pursuant to the Registration Rights Agreement, or (z) the expiration or earlier termination of this Warrant if the Warrant has not been exercised in full or in
part on such date, use all commercially reasonable efforts to timely file all reports required under the 1934 Act and otherwise timely take all actions necessary to permit the Warrantholder to sell or otherwise dispose of this Warrant and the shares
of Common Stock issued on exercise hereof pursuant to Rule 144 promulgated under the Act as amended and in effect from time to time, provided that the foregoing shall not apply in the event of a Merger Event following which the successor or
surviving entity is not subject to the reporting requirements of the 1934 Act. If the Warrantholder proposes to sell Common Stock issuable upon the exercise of this Agreement in compliance with Rule 144, then, upon Warrantholder’s written
request to the Company, the Company shall furnish to the Warrantholder, within five (5) business days after receipt of such request, a written statement confirming the Company’s compliance with the filing and other requirements of such
Rule 144. 
 SECTION 10. REPRESENTATIONS AND COVENANTS OF THE WARRANTHOLDER. 

This Agreement has been entered into by the Company in reliance upon the following representations and covenants of the Warrantholder: 

(a) Investment Purpose. This Warrant and the shares issued on exercise hereof will be acquired for investment and not with a view
to the sale or distribution of any part thereof in violation of applicable federal and state securities laws, and the Warrantholder has no present intention of selling or engaging in any public distribution of the same except pursuant to a
registration or exemption. 
 (b) Private Issue. The Warrantholder understands (i) that the Common Stock issuable upon
exercise of this Agreement is not, as of the Effective Date, registered under the Act or qualified under applicable state securities laws, and (ii) that the Company’s reliance on exemption from such registration is predicated on the
representations set forth in this Section 10. 
 (c) Financial Risk. The Warrantholder has such knowledge and experience
in financial and business matters as to be capable of evaluating the merits and risks of its investment, and has the ability to bear the economic risks of its investment. 

(d) Accredited Investor. Warrantholder is an “accredited investor” within the meaning of Rule 501 of Regulation D
promulgated under the Act, as presently in effect, and Warrantholder is knowledgeable, sophisticated and experienced in making, and is qualified to 

  
 9 








 
make decisions with respect to, investments in shares presenting an investment decision like that involved in the purchase of the Common Stock and the Warrant, including investments in securities
issued by the Company and investments in comparable companies, and has requested, received, reviewed and considered all information it deemed relevant in making an informed decision to purchase the Warrant. 

SECTION 11. TRANSFERS. 

Subject to compliance with applicable federal and state securities laws, this Agreement and all rights hereunder are transferable, in whole or
in part, without charge to the holder hereof (except for transfer taxes) upon surrender of this Agreement properly endorsed. Each taker and holder of this Agreement, by taking or holding the same, consents and agrees that this Agreement, when
endorsed in blank, shall be deemed negotiable, and that the holder hereof, when this Agreement shall have been so endorsed and its transfer recorded on the Company’s books, shall be treated by the Company and all other persons dealing with this
Agreement as the absolute owner hereof for any purpose and as the person entitled to exercise the rights represented by this Agreement. The transfer of this Agreement shall be recorded on the books of the Company upon receipt by the Company of a
notice of transfer in the form attached hereto as Exhibit III (the “Transfer Notice”), at its principal offices and the payment to the Company of all transfer taxes and other governmental charges imposed on such transfer. Until the
Company receives such Transfer Notice, the Company may treat the registered owner hereof as the owner for all purposes. 
 SECTION 12.
MISCELLANEOUS 
 (a) Effective Date. The provisions of this Agreement shall be construed and shall be given effect in all
respects as if it had been executed and delivered by the Company on the date hereof. This Agreement shall be binding upon any successors or assigns of the Company. 

(b) Remedies. In the event of any default hereunder, the non-defaulting party may proceed to protect and enforce its rights
either by suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action for specific performance for any default where Warrantholder will not have an adequate remedy at
law and where damages will not be readily ascertainable. 
 (c) No Impairment of Rights. The Company will not, by amendment of
its Charter or through any other means, avoid or seek to avoid the observance or performance of any of the terms of this Agreement, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such
actions as may be necessary or appropriate in order to protect the rights of the Warrantholder against impairment. 
 (d)
Severability. In the event any one or more of the provisions of this Agreement shall for any reason be held invalid, illegal or unenforceable, the remaining provisions of this Agreement shall be unimpaired, and the invalid, illegal or
unenforceable provision shall be replaced by a mutually acceptable valid, legal and enforceable provision, which comes closest to the intention of the parties underlying the invalid, illegal or unenforceable provision. 

  
 10 








 (e) Notices. Except as otherwise provided herein, any notice, demand, request,
consent, approval, declaration, service of process or other communication that is required, contemplated, or permitted under this Agreement or with respect to the subject matter hereof shall be in writing, and shall be deemed to have been validly
served, given, delivered, and received upon the earlier of: (a) personal delivery to the party to be notified, (b) when sent by confirmed telex, electronic transmission or facsimile if sent during normal business hours of the recipient, if
not, then on the next business day, (c) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one day after deposit with a nationally recognized overnight courier, specifying
next day delivery, with written verification of receipt, and shall be addressed to the party to be notified as follows: 
 If to
Warrantholder: 
 If to the Company: 

CLEVELAND BIOLABS, INC. 

Attention: Chief Executive Officer 

73 High Street 
 Buffalo, NY 14203

 Facsimile: 716-849-6820 

Telephone: 716-849-6810 
 Email:
Notices@cbiolabs.com 
 or to such other address as each party may designate for itself by like notice. 

(f) Entire Agreement; Amendments. This Agreement constitutes the entire agreement and understanding of the parties hereto in
respect of the subject matter hereof, and supersedes and replaces in their entirety any prior proposals, term sheets, letters, negotiations or other documents or agreements, whether written or oral, with respect to the subject matter hereof. None of
the terms of this Agreement may be amended except by an instrument executed by each of the parties hereto. 
 (g) Headings. The
various headings in this Agreement are inserted for convenience only and shall not affect the meaning or interpretation of this Agreement or any provisions hereof. 

  
 11 








 (h) No Strict Construction. The parties hereto have participated jointly in the
negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise
favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement. 
 (i) No Waiver. No
omission or delay by Warrantholder at any time to enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by Warrantholder at any time designated, shall be a waiver of any such right
or remedy to which Warrantholder is entitled, nor shall it in any way affect the right of Warrantholder to enforce such provisions thereafter during the term of this Agreement. 

(j) Survival. All agreements, representations and warranties contained in this Agreement or in any document delivered pursuant
hereto shall be for the benefit of Warrantholder and shall survive the execution and delivery of this Agreement and the expiration or other termination of this Agreement. 

(k) Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be
governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Both party agree that all legal proceedings concerning the interpretations,
enforcement and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the
adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and
agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party
hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such
party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to
serve process in any other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Agreement, then the prevailing party in such action, suit or proceeding shall be reimbursed by the
other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. 

(l) Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of
counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. 

  
 12 








 (m) Lost, Stolen, Mutilated or Destroyed Warrant. If this Warrant is lost, stolen,
mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination and tenor as
this Warrant so lost, stolen, mutilated or destroyed. Any such new Warrant shall constitute an original contractual obligation of the Company, whether or not the allegedly lost, stolen, mutilated or destroyed Warrant shall be at any time enforceable
by anyone. 
 (n) Legends. To the extent required by applicable laws, this Warrant and the shares of Common Stock issuable
hereunder (and the securities issuable, directly or indirectly, upon conversion of such shares of Common Stock, if any) may be imprinted with a restricted securities legend in substantially the following form: 

THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY APPLICABLE STATE SECURITIES
LAWS, AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR PURSUANT TO RULE 144 OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND
ANY APPLICABLE STATE SECURITIES LAWS. 
 (o) This Warrant has been made in Russian and English language. In the event of a conflict or
inconsistency between the English and Russian versions of the Warrant, the English version shall prevail. 
 [REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK] 

  
 13 








 IN WITNESS WHEREOF, the parties hereto have caused this Warrant Agreement to be executed by its
officers thereunto duly authorized as of the Effective Date. 
  

			
	COMPANY:
	
	CLEVELAND BIOLABS, INC.
		
	By:	 	  

	Name:	 	Yakov Kogan, Ph.D., MBA
	Title:	 	Chief Executive Officer
	
	 WARRANTHOLDER:
  




  
 14 








 EXHIBIT I 

NOTICE OF EXERCISE 
 To:
                                         
                                

(1) The undersigned Warrantholder hereby elects to purchase [            ]
shares of the Common Stock of [                    ], pursuant to the terms of the Agreement dated the [    ] day of
[            ,             ] (the “Agreement”) between
[                    ] and the Warrantholder, and tenders herewith payment of the Purchase Price in full, together with all applicable transfer
taxes, if any. [NET ISSUANCE: elects pursuant to Section 3(b) of the Agreement to effect a Net Issuance.] 
 (2) Please issue a
certificate or certificates representing said shares of Common Stock in the name of the undersigned or in such other name as is specified below. 

(3) [Please make a book entry representing said shares of Common Stock in the name of the undersigned or in such other name as is
specified below and make such shares available pursuant to the attached instructions via the Depository Trust Company’s Deposit or Withdrawal at Custodian (“DWAC”) system.] 

 

			
	(Name)	 	 
		
	(Address)	 	 
	 	 	 
	
	WARRANTHOLDER:
		
	Name:	 	 
		
	Title:	 	 



  
 15 








 EXHIBIT II 

ACKNOWLEDGMENT OF EXERCISE 

The undersigned [                    ],
hereby acknowledge receipt of the “Notice of Exercise” from [                    ], to purchase
[            ] shares of the Common Stock of [                    ], pursuant to the
terms of the Agreement, and further acknowledges that [            ] shares remain subject to purchase under the terms of the Agreement. 

 

			
	COMPANY:
	
	CLEVELAND BIOLABS, INC.
		
	By:	 	  

	Name:	 	Yakov Kogan, Ph.D., MBA
	Title:	 	Chief Executive Officer
		
	Date:	 	  




  
 16 








 EXHIBIT III 

TRANSFER NOTICE 
 (To
transfer or assign the foregoing Agreement execute this form and supply required information. Do not use this form to purchase shares.) 

FOR VALUE RECEIVED, the foregoing Agreement and all rights evidenced thereby are hereby transferred and assigned to 

 
  

(Please Print) 
  

			
	whose address is	  	 

  
  

 

			
	Dated:	  	 

  

			
	Holder’s Signature:	  	 

  

			
	Holder’s Address:	  	 

  

			
	Signature Guaranteed:	  	 

  

	NOTE:	The signature to this Transfer Notice must correspond with the name as it appears on the face of the Agreement, without alteration or enlargement or any change whatever. Officers of corporations and those acting in a
fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Agreement. 


  
 17